|
Video: What is a Stock Split?
|
|
RXi Pharmaceuticals is a clinical-stage company developing therapeutics based on its self-delivering RNAi (sd-rxRNA®) platform and Samcyprone, a topical immunomodulator. Co.'s clinical development programs include RXI-109, an sd-rxRNA for the treatment of dermal and ocular scarring, and Samcyprone, for the treatment of warts. Co.'s development programs also include cell-based cancer immunotherapy. Co.'s RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its topical immunotherapy agent, Samcyprone, treats diseases by inducing, enhancing or suppressing an immune response in the skin. According to our RXII split history records, RXII has had 2 splits. | |
|
RXII (RXII) has 2 splits in our RXII split history database. The first split for RXII took place on April 18, 2016. This was a 1 for 10 reverse split, meaning for each 10 shares of RXII owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split. RXII's second split took place on January 08, 2018. This was a 1 for 10 reverse split, meaning for each 10 shares of RXII owned pre-split, the shareholder now owned 1 share. For example, a 100 share position pre-split, became a 10 share position following the split.
When a company such as RXII conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the RXII split history from start to finish, an original position size of 1000 shares would have turned into 10 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into RXII shares, starting with a $10,000 purchase of RXII, presented on a split-history-adjusted basis factoring in the complete RXII split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/09/2014 |
|
End date: |
11/16/2018 |
|
Start price/share: |
$203.00 |
|
End price/share: |
$0.33 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.84% |
|
Average Annual Total Return: |
-80.41% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$16.25 |
|
Years: |
3.94 |
|
|
|
Date |
Ratio |
04/18/2016 | 1 for 10 | 01/08/2018 | 1 for 10 |
|
|